Let's talk about time of enrollment which reflects real world reality of people seeking testing and then seeking care. With the trial there is an inherent delay to consent, enroll, and ship drug. 44% of participants started within 4 days of symptom onset.
Best figure in #ivermectin manuscript (actually the Appendix) is eFigure4, which I pushed for inclusion. Regardless of how early one started IVM after #covid19 symptom onset, no benefit was observed regarding duration of symptons, including with those with severe symptoms.
Time to start therapy could be very important if #ivermectin actually had anti-viral properties in humans. It does not.
The Covid-Out trial looked at viral load change over time
More on that later today.
Covid_Out trial data presented at CROI today on the lack of virologic effect for #ivermectin when compared to an identical matched placebo control. There is not an antiviral effect when dosed at 400 mcg/kg/day for 3 days.
Medications can have immunomodulatory effects or other potential mechanisms for clinical benefit which could be not directly or indirectly antiviral by mechanism. But -- in neither the TogetherTrial or Covid-Out was any antiviral effect observed with IVM in humans.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
COVID-Out double-blind randomized trial tested #metformin, ivermectin, or fluvoxamine for outpatient #COVID19. Secondary endpoint was incidence of Long Covid (PASC).
Volunteers were followed monthly to 10 mo.
Metformin 42% reduction in Long Covid. medrxiv.org/content/10.110…
Incidence of Healthcare provider diagnosed long covid (PASC) was 42% less among those randomized to #metformin vs. matched placebo.
Hazard Ratio for Long Covid in the metformin group versus control was 0.58 (95% CI 0.38 to 0.88, P=0.009);
There was no benefit for those randomized to #ivermectin vs. matched placebo for reducing long covid and low-dose #fluvoxamine was not beneficial either for decreasing #longcovid.